917771-41-6

Basic information

• Product Name: 4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzoic acid methyl ester
• Synonyms: 4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzoic acid methyl ester
• CAS NO: 917771-41-6
• Molecular Weight: 248.202
• Mol File: 917771-41-6.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: 4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzoic acid methyl ester(917771-41-6)
• EPA Substance Registry System: 4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzoic acid methyl ester(917771-41-6)

Safety Data

• Hazardous Substances Data: 917771-41-6(Hazardous Substances Data)

Upstream product

• 27607-77-8 trimethylsilyl trifluoromethanesulfonate 
• 3609-53-8 methyl 4-acetylbenzoate 
• 81290-20-2 (trifluoromethyl)trimethylsilane 

Downstream Products

• 1189852-19-4 N-(1-chloropyrazolo[1,5-a]pyrimidin-5-yl)-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide 
• 1189852-18-3 4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzoic (isobutylcarbonic)anhydride 
• 1093853-70-3 1,1,1-trifluoro-2-(4-(4-(1-tosylpiperidin-4-yl)oxazol-5-yl)phenyl)propan-2-ol 
• 1093853-68-9 2-(4-(4-cyclohexyloxazol-5-yl)phenyl)-1,1,1-trifluoropropan-2-ol 
• 1093853-69-0 4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzaldehyde 

Relevant articles and documents

Hydroxypurine compound and use thereof

The invention discloses a hydroxypurine compound and a use of the hydroxypurine compound as a PDE2 or TNFa inhibitor and concretely discloses a compound shown in the formula (I) and its tautomer or pharmaceutically acceptable salt.

ROR GAMMA (RORY) MODULATORS

The present invention relates to novel compounds according to Formula I or a pharmaceutically acceptable salt thereof wherein the variables are as defined in the claims. The compounds can be used as inhibitors of RORγ and are useful for the treatment of R

BTK protein kinase inhibitors

This application discloses pyridine and pyrimidine compounds according to formula I wherein R1, R2, R3, R4, R5, X1 and A are as described herein which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of formula I and at least one carrier, diluent or excipient.